Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Biden gets second booster shot, pushes for more COVID funding

Published 03/30/2022, 09:32 AM
Updated 03/30/2022, 05:12 PM
© Reuters. FILE PHOTO: A health care administer gives the second dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine to a person at the L.A. Care Health Plan free testing and vaccination site at the First African Episcopal Church in Los Angeles, Calif

By Trevor Hunnicutt

WASHINGTON (Reuters) -U.S. President Joe Biden rolled up his sleeve for a second COVID-19 booster shot on Wednesday as his administration rolled out efforts to help Americans live with the coronavirus, including a new website and a renewed push for vaccinations and funding.

"If we fail to invest, we leave ourselves vulnerable if another wave hits," Biden said in remarks at the White House to launch COVID.gov, a clearinghouse of information aimed at helping people manage the virus as they seek a return to normalcy.

On Tuesday, U.S. health officials authorized a second booster shot for Americans age 50 and older and those who are immunocompromised, two years after the start of the pandemic.

Biden, 79, received his fourth dose of the Pfizer (NYSE:PFE) Inc/BioNTech SE vaccine. A second booster of Moderna (NASDAQ:MRNA) Inc's shot also was authorized.

Several drugstore chains, including CVS Health (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA), said they would start offering second booster doses.

Nearly 982,000 people in the United States have died from COVID since early 2020 over several waves of the disease, according to a Reuters analysis of local data.

Although vaccines and increasingly available therapies for COVID-19 have reduced severe illness and deaths, public health officials are monitoring BA.2, an Omicron subvariant that now accounts for more than half of all U.S. cases.

U.S. officials have said they do not expect another major surge, but noted COVID cases could rise from BA.2 or a subsequent variant, reflecting the administration's position that the country must learn to live with and adapt to some level of this coronavirus.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Biden has asked Congress for another tranche of funding to pay for current vaccinations and treatments, as well as to shore up the nation's preparedness for future outbreaks.

"We need to secure additional supply now," he said on Wednesday, warning free COVID vaccines may not be available this autumn without more funds, especially if a new vaccine is needed. "Congress, please act... immediately. The consequences of inaction are severe."

Biden, who had sought $22.5 billion, this month warned the U.S. government would run out of funding for supplies without more support.

Lawmakers lowered the amount before dropping it altogether from the most recent government funding bill, with congressional Democrats saying they will take up COVID funding separately.

No. 2 House Democrat Representative Steny Hoyer told reporters that he hopes the chamber can vote on a separate COVID measure next week if the Senate can reach an agreement.

U.S. Centers for Disease Control and Prevention Director Rochelle Walensky and other senior Biden administration health officials are scheduled to update lawmakers at a U.S. House hearing on Wednesday afternoon.

Several members of the White House communications office, including Jen Psaki, recently tested positive for COVID.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.